Evidence map›Paper›PMID 38268762›Full record

ArticleFrontiers in chemistry2023

Dual COX-2/5-LOX inhibitors from

Yong-Qiang Tian, Jing Liu, Peng Cheng, Jian Zou, Hui-Fang Xu, Xin-Hua Shi, Yi-Sheng Zhang, Ling Mei

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yong-Qiang Tian *Department of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Jing Liu *Department of Acupuncture, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Peng Cheng *Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jian ZouDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Hui-Fang XuDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Xin-Hua ShiDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Yi-Sheng ZhangDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Ling MeiDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Third Clinical Medical College of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Hubei University of Chinese Medicine · CNWuhan City Chinese Medicine Hospital · CNCentral Hospital of Wuhan · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclooxygenase 2 (COX-2) and 5-lipoxygenase (5-LOX) are overexpressed in gastric cancer cells, the dual inhibitors of which exhibit potential against metastasis and invasion with fewer side effects. To discover inhibitors targeting COX-2 and 5-LOX, we conducted ultrafiltration and enrichment calculation to screen candidates in quaternary alkaloids (QAs) from

Indexed as

5-LOX inhibitorsCOX-2 inhibitorsgastric cancer cellshormone pathwaysultrafiltrationZanthoxylum simulans

Identifiers

PMID38268762
PMCPMC10805830
OpenAlexW4390698893

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.